Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

April 30, 2000

Primary Completion Date

July 31, 2002

Conditions
Breast Cancer
Interventions
DRUG

pegylated liposomal doxorubicin hydrochloride

Trial Locations (14)

20157

Mario Negri Institute for Pharmacological Research, Milano (Milan)

28041

Hospital Universitario 12 de Octubre, Madrid

33076

Institut Bergonie, Bordeaux

49100

Rabin Medical Center - Beilinson Campus, Petah Tikva

63011

Centre Jean Perrin, Clermont-Ferrand

75248

Institut Curie - Section Medicale, Paris

76038

Centre Henri Becquerel, Rouen

A-1100

Ludwig Boltzmann - Institute for Applied Cancer Research, Vienna

GR-45110

University of Ioannina, Ioannina

00161

Istituti Fisioterapici Ospitalieri - Roma, Rome

9713 EZ

Academisch Ziekenhuis Groningen, Groningen

NL-6500 HB

University Medical Center Nijmegen, Nijmegen

Ch-1272

Clinique De Genolier, Genolier

SW3 6JJ

Royal Marsden NHS Trust, London

All Listed Sponsors
lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT00005980 - Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter